Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 23, Issue 3, Pages 377-382Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2011.03.006
Keywords
-
Categories
Funding
- Oxford Biomedical Research Center
- Oxford Martin School
- Meningitis UK
Ask authors/readers for more resources
A little more than a decade after the explosion of research into recombinant live-attenuated or replication-deficient viruses as vaccine platforms, many viral vector-based vaccines have been licensed for animals. Progress has been slower for humans but 2011 will see the licensure of the first viral-vectored vaccine for humans, against Japanese Encephalitis. In addition a vaccine with a viral-vectored component showed efficacy against HIV infection in humans. Viral-based vaccines have an excellent safety profile but must deal with the potential problem of pre-existing anti-vector immunity. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vectors are approaching their final years as vaccine 'candidates' rather than vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available